Corvus Pharma Com (CRVS) Stock Price, Quote & News

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psori...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 900 4520

Website: www.corvuspharma.com

Address:

901 Gateway Boulevard, Third Floor, South San Francisco, United States

MedicalDoctorInvestor Feb. 3 at 10:10 PM

$CRVS Hi Everyone, I know many of you have been asking about me in recent weeks. I am here and just have been very busy with some personal ventures. Many of you have asked about the cyber truck and I must sadly inform you that I’ve decided to hold off on purchasing the second truck for now until market conditions improve. My best wishes to all my fans and followers. 🙏 god bless

1 · Reply

tradingjunk321 Feb. 3 at 9:41 PM

$CRVS Moore and Moore

1 · Reply

Thedeuceze Feb. 3 at 7:43 PM

$CRVS parmership tomorrow for type 1 diabetes

1 · Reply

dwsrph1 Feb. 3 at 6:12 PM

$CRVS Novo Nordisk (NVO) stock was halted on Tuesday, February 3, 2026, around 11:35 AM EST due to "news pending," before plunging roughly 13%-14%. The halt followed a grim 2026 outlook with expected sales declines and mixed 2025 results. The company expects a 5% to 13% sales drop in 2026.

2 · Reply

mohamettarik Feb. 3 at 6:00 PM

$CRVS 👉 Bear flag / weak consolidation

2 · Reply

Thedeuceze Feb. 3 at 5:48 PM

$CRVS green on a down day. Shorts are trapped.

0 · Reply

tradingjunk321 Feb. 3 at 4:39 PM

$CRVS NVO halted news pending, 😂 our day coming Moore to come!

1 · Reply

dwsrph1 Feb. 3 at 3:44 PM

$CRVS long and strong!

1 · Reply

TimeTaEat Feb. 3 at 3:36 PM

$CRVS $22 puts still ITM 👏🏼

0 · Reply

Jellysquid1 Feb. 3 at 2:06 PM

$CRVS Crvs Has the Momentum! Bulls are getting Wealthier While bears are jumping ships( row boats)

1 · Reply

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 21, 2026, 10:53 PM EST - 13 days ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 2:50 PM EST - 13 days ago

Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon

Jan 21, 2026, 11:43 AM EST - 13 days ago

Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know

Jan 20, 2026, 5:15 PM EST - 14 days ago

Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript

Jan 20, 2026, 4:01 PM EST - 14 days ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 2:10 PM EST - 14 days ago

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:00 PM EST - 14 days ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 16, 2026, 4:01 PM EST - 18 days ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Nov 4, 2025, 7:16 PM EST - 3 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 31, 2025, 7:30 AM EDT - 3 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 28, 2025, 4:01 PM EDT - 3 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 17, 2025, 10:00 AM EDT - 3 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 2, 2025, 4:01 PM EDT - 4 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Aug 12, 2025, 11:31 PM EDT - 6 months ago

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

Aug 8, 2025, 3:20 PM EDT - 6 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Jun 4, 2025, 7:00 AM EDT - 8 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 28, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 11:57 AM EDT - 9 months ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 8, 2025, 11:06 PM EDT - 9 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:02 PM EDT - 9 months ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 9 months ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 23, 2025, 4:08 PM EDT - 10 months ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 9, 2025, 4:01 PM EDT - 10 months ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Mar 28, 2025, 9:30 AM EDT - 11 months ago

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Mar 28, 2025, 9:29 AM EDT - 11 months ago

Corvus Pharmaceuticals: Now At Cruising Altitude

Mar 25, 2025, 7:58 PM EDT - 11 months ago

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 8:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 19, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 1:36 PM EST - 1 year ago

Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 13, 2024, 1:18 PM EST - 1 year ago

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13, 2024, 12:02 AM EST - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

MedicalDoctorInvestor Feb. 3 at 10:10 PM

1 · Reply

tradingjunk321 Feb. 3 at 9:41 PM

$CRVS Moore and Moore

1 · Reply

Thedeuceze Feb. 3 at 7:43 PM

$CRVS parmership tomorrow for type 1 diabetes

1 · Reply

dwsrph1 Feb. 3 at 6:12 PM

2 · Reply

mohamettarik Feb. 3 at 6:00 PM

$CRVS 👉 Bear flag / weak consolidation

2 · Reply

Thedeuceze Feb. 3 at 5:48 PM

$CRVS green on a down day. Shorts are trapped.

0 · Reply

tradingjunk321 Feb. 3 at 4:39 PM

$CRVS NVO halted news pending, 😂 our day coming Moore to come!

1 · Reply

dwsrph1 Feb. 3 at 3:44 PM

$CRVS long and strong!

1 · Reply

TimeTaEat Feb. 3 at 3:36 PM

$CRVS $22 puts still ITM 👏🏼

0 · Reply

Jellysquid1 Feb. 3 at 2:06 PM

$CRVS Crvs Has the Momentum! Bulls are getting Wealthier While bears are jumping ships( row boats)

1 · Reply

FutureOpt Feb. 3 at 1:13 PM

$CRVS Massive puts loaded!!!

2 · Reply

tradingjunk321 Feb. 3 at 8:29 AM

$CRVS Since data was released, CRVS has traded Moore than 139 million shares, w/ recent offering there is roughly 83,777,000 shares outstanding. Since data released CRVS has closed every single day (10 trading days) over $20.54 or higher. CRVS is for sure consolidating and building a base, next news release Moore than likely something like a Goldman Sach buy report that puts this back over $25+ with help of the beautiful shorts! Stay tuned for Moore!

0 · Reply

fubar444 Feb. 3 at 1:14 AM

$CRVS this is a buyout and very bullish signal very

1 · Reply

Jellysquid1 Feb. 2 at 9:34 PM

$CRVS CRVS Has The Momentum! 2026 Is Our Year!

0 · Reply

Mr_Predicto Feb. 2 at 9:11 PM

$CRVS That was a serious fade today from 6+ percent to 1.5 percent. Can’t even blame the Nasdaq for the decline. Prediction: Crystal ball shows a painting sitting in the sun. The sun transforms the painting from a vibrant artwork to a blank canvas.

2 · Reply

ObserverOne Feb. 2 at 7:17 PM

$CRVS the stock is consolidating and building a new baseline. It appears to be around 21 right now. I am out of the stock at 24, may regret it, but had to do it. My cost basis was 3.5.

5 · Reply

tradingjunk321 Feb. 2 at 6:48 PM

$CRVS Buyout will happen! Impeccably Moore to come!

1 · Reply

fubar444 Feb. 2 at 5:41 PM

$CRVS aside from a buyout or other impending positive news, when have you seen options exercised in advance like this? Message sent. Message received.

2 · Reply

mohamettarik Feb. 2 at 5:36 PM

$CRVS $5 ... fantastic... this how people really make moeny

0 · Reply

Butt_Coin Feb. 2 at 5:29 PM

$CRVS Going down, soon will turn red

0 · Reply

dwsrph1 Feb. 2 at 5:23 PM

$CRVS Houston. Shorts may have a problem 📞

1 · Reply

tradingjunk321 Feb. 2 at 3:29 PM

$CRVS Ok folks Soquelitinib is not safe! It's Moore like "Impeccable Safe" now take that to the bank with much Moore appreciation to come! Moore and Moore to come! This is from Dr. Sergei Grando 😊

1 · Reply

Market Cap	1.73B
Revenue (ttm)	0.00
Net Income (ttm)	-62.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,549,500
Avg Vol	3,987,028
Day's Range	N/A - N/A
Shares Out	83.77M
Stochastic %K	17%
Beta	0.70
Analysts	Strong Sell
Price Target	$30.50